2 Title:

1

- 3 "Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin
- 4 Versus Hydroxychloroguine and Placebo in Patients with Mild COVID-19:
- 5 Randomized, double blind, Placebo controlled trial"
- 6 Authors
- 7 Ivonne A Roy-García¹, Moises Moreno-Noguez², Rodolfo Rivas-Ruiz^{1*}, Marta
- 8 Zapata-Tarres ³⁸, Marcela Perez-Rodriguez¹⁸, Magaly A Ortiz-Zamora⁴, Lourdes
- 9 Gabriela Navarro-Susano⁴, Lilia M Guzman-Rivas⁵, Luis Rey Garcia-Cortes⁶, Icela
- 10 Palma-Lara⁷, Pedro Gutierrez-Catrellón^{3,8, #a, #b.}
- 1. Centro de Adiestramiento en Investigación Clínica, División de Investigación
- 13 Clínica, Instituto Mexicano del Seguro Social, México.
- 14 2. Unidad de Medicina Familiar #55 Zumpango, Órgano de Operación
- 15 Administrativa Desconcentrada Estado de México Oriente, Instituto Mexicano
- del Seguro Social, México.
- 17 3. Fundación IMSS, A.C, México
- 4. Unidad de Medicina Familiar #28, Instituto Mexicano del Seguro Social,
- 19 México.
- 5. Unidad de Medicina Familiar #52 Cuautitlán Izcalli, Órgano de Operación
- 21 Administrativa Desconcentrada Estado de México Oriente, Instituto Mexicano
- del Seguro Social, México.

6. Coordinación Auxiliar Médica de Investigación en Salud, Órgano de
Operación Administrativa Desconcentrada Regional Estado de México
Oriente, Instituto Mexicano del Seguro Social, México.

7. Centro de Investigación Translacional en Ciencias de la Salud, México
Hospital Dr. Manuel Gea González, México

* Corresponding author
Email:rivasrodolfo@gmail.com (RR)

Abstract

32

3334

38

- 35 To determine the efficacy and safety of fixed combination of
- 36 hydroxychloroquine/azithromycin (HCQ+AZT) compared to hydroxychloroquine
- 37 (HCQ) alone or placebo in mild COVID-19 outpatients to avoid hospitalization.

Materials and methods

- 39 This randomized, parallel, double-blind clinical trial included male and female
- 40 patients aged 18 and 76 years non COVID vaccinated, who were diagnosed with
- 41 mild COVID-19 infection. All patients underwent liver and kidney profile test, as well
- 42 as a health questionnaire and clinical revision to document that they did not have
- 43 uncontrolled comorbidities. They were randomly assigned to one of the three
- 44 treatment arms: 1) hydroxychloroguine with azithromycin 200 mg/250 mg every 12
- 45 hours for five days followed by hydroxychloroguine 200 mg every 12 hours for 5
- 46 days; 2) hydroxychloroguine 200 mg every 12 hours for ten days; or 3) placebo every
- 47 12 hours for ten days. The primary outcome of the study was hospitalization, while
- 48 the secondary outcomes were disease progression, pneumonia, use of
- 49 supplemental oxygen, and adverse events. This study was registered in
- clinicaltrials.gov with the NCT number of 04964583.

Results

- A total of 92 participants were randomized. Of whom, 30 received HCQ+AZT, 31
- 53 received HCQ, and 31 received placebo. The median age was 37 years, 27.2% of
- 54 the participants had comorbidities, and the global incidence of hospitalization was

2.2%. The incidence of hospitalization was 6.7% (2/30) in the HCQ+AZT group compared to the HCQ or placebo groups, in which there were no hospitalizations. Progression of disease was higher in the HCQ group [RR=3.25 (95% CI, 1.19-8.87)] compared with placebo group. There was no statistical difference between the HCQ+AZT group and the placebo group in progression of disease. The incidence of pneumonia was 30% in the HCQ+AZT group, 32.2% in the HCQ group, and 9.6% in the placebo group (HCQ + AZT vs Placebo; p=0.06). There was a significant risk of pneumonia versus placebo only in the HCQ group [RR=3.33 (95% CI, 1.01-10.9)]. Supplemental oxygen was required by 20% (6/30) of the patients in the HCQ+AZT group, 6.4 (2/31) of the patients in the HCQ group, and 3.2% (1/31) of the patients in the placebo group, [(HCQ + AZT vs Placebo; p=0.100), (HCQ vs Placebo, p=0.610)]. There was no statistical difference between groups for negative test (PCR) on day 11. The most frequent adverse events were gastrointestinal symptoms. No lengthening of the QT interval was observed in patients receiving HCQ+AZT or HCQ.

Conclusion

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

73

- 71 The use of HCQ+AZT does not decrease the risk of hospitalization in patients with
- mild COVID-19. The use of HCQ increases the risk of progression and pneumonia.

Introduction

75 76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

At the end of December 2019, a new viral infection belonging to the Coronavirus family emerged in China [1], which spread rapidly worldwide [2] and was declared a pandemic by the WHO in March 2020. The COVID-19 disease requires hospitalization in 20% of patients, 33.7% of whom require admission to the intensive care unit, with a mortality rate reaching up to 62.4% [3]. The need to find an urgent treatment to reduce the impact of the pandemic has led to the use of different therapeutic options, among them is the fixed combination of hydroxychloroquine and azithromycin which became a promising option [4,5]. Hydroxychloroquine has antiviral activity, inhibits endosome acidification, interferes with virus fusion to the cell, exhibits non-specific antiviral activity in vitro against a wide range of emerging viruses (HIV, dengue, hepatitis C, SARS, and MERS), and more recently against SARS CoV-2 in addition to its anti-inflammatory activity [6,7]. On the other hand, azithromycin is a macrolide antibiotic indicated for airway infections, which has shown anti-inflammatory and antiviral effects in vitro [8], which is why it was proposed as an accessible and cost-effective option for SARS CoV-2 infection [9]. Even if these drugs have demonstrated efficacy in vitro nowadays, clinical results on the beneficial effect of the fixed combination HCQ+AZT in hospitalized or mechanically ventilated patients are inconsistent [10,11], which is attributed to the delayed initiation of treatment when viral replication and inflammatory response characterized by an increased cytokine storm have already occurred [12]. Therefore, it is hypothesized that early use of these drugs is necessary to achieve benefits to

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116117

118

119

120

121

prevent hospitalizations. This study aimed at determining the efficacy and safety of the fixed combination of HCQ+AZT compared to HCQ or placebo in mild COVID-19 outpatients to avoid hospitalizations [13]. Methods Trial design This study was designed as a multicenter, parallel, double-blind, randomized clinical trial. The study was conducted in two public ambulatory family medicine units, in Mexico City (UMF No. 28) and at the State of México (UMF No. 52) both of the Instituto Mexicano del Seguro Social (IMSS), which is the national social security institute. The trial was designed and conducted by the authors. The protocol was approved by the National Research Committee institution's review board of the IMSS with the number R-2020-785-138 and by COFEPRIS, the Mexican drug regulatory agency. Written informed consent was obtained from each of the included participants. Ultra laboratories were the sponsor of the study; nonetheless, they were not involved in protocol or the analysis of results or in the preparation of the manuscript. The trial was registered in clinicatrials.gov (Clinical Trials: NCT04964583). This report follows the CONSORT guidelines. Eligible subjects The study included patients aged 18-76 years who were diagnosed with mild COVID-19 with acute respiratory disease and who met the current operational definition of the Ministry of Health of Mexico, which included the presence of a major symptom such as headache, fever, cough, dyspnea, and any of the following minor symptoms: myalgia, arthralgia, odynophagia, chills, chest pain, rhinorrhea, anosmia, dysgeusia,

or conjunctivitis [14]. The diagnosis was confirmed by RT-PCR for SARS-CoV-2, the severity of the disease was evaluated with the NEWS scale, patients with a score ≤4 points were considered to have mild disease. Patients with cardiac disorders with delayed cardiac conduction (QT segment ≥ 450 ms), pregnant or lactating women, patients with hypersensitivity to study drugs, patients with chronic renal failure with (eGFR<40 mL/min), patients with a history of retinopathy or macular degeneration, known Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency, patients with liver disease, cirrhosis or those using the following medications: colchicine, ergotamine, dihydroergotamine, citalopram, hydroxyzine, domperidone, piperazine, antiarrhythmic drugs class IA and III and antidepressant medications were excluded from the study.

Intervention

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

Participants were randomly assigned to one of the three treatment arms. The participants in Group 1 (HCQ+AZT) received hydroxychloroquine 200 mg/azithromycin 250 mg orally every 12 hours for 5 days, followed by hydroxychloroguine 200 mg every 12 hours for 5 more days. The participants in Group 2 (HCQ) received only hydroxychloroguine 200 mg orally every 12 hours for 10 days. The participants in Group 3 received an oral placebo every 12 hours for 10 days. All three treatment groups received symptomatic treatment for the management of COVID-19, the current standard was at discretion of the treating physician based on acetaminophen, non-steroidal analgesics, antihistamines and Ivermectin. A computerized random number sequence was generated for assignment to study treatment groups and was stratified according to center. Randomization was carried out by one of the investigators who did not participate in

the inclusion of patients or in the delivery of medication. The medical staff was responsible for the recruitment and selection of participants and the evaluation of the correct allocation of treatment according to the randomization. Adherence to treatment was evaluated by counting the tablets during the medical consultation and by the intake recorded by the participants in the digital application for smartphones.

Follow-up

146

147

148

149

150

151152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

The follow-up was carried out through a Web App on a smartphone explicitly elaborated for the research project (digital monitoring), for which the participant was previously instructed, recording the medication intake, adverse events, oxygen saturation, and temperature during the ten days of the treatment. A clinical examination was performed at the time of inclusion, on days 6 and 11 after initiating the treatment, in which an evaluation of the severity of the disease was carried out along with an RT-PCR test, electrocardiogram and follow-up laboratory studies, count of tablets to evaluate therapeutic adherence, and radiography taken at the beginning of the study and on day 11. On day 21 of the follow-up, the participants were called by phone to evaluate symptoms and to investigate whether the patient had returned to routine activities, required hospitalization, or had any of the secondary outcomes. All participants who showed a change suggestive of deterioration (oxygen saturation less than 90% in room air, and shortness of breath or pneumonia) during their digital follow-ups were contacted by a specialized physician to confirm the data and establish the behavior to follow.

181

168 Outcomes 169 The primary outcome of the study was hospitalization during the 21 days of the 170 follow-up. The secondary outcomes included disease progression, which was defined by oxygen saturation less than 90%, dyspnea, or pneumonia [15], use of 172 supplemental oxygen, the presence of adverse events during the 21 days of follow-173 up, and PCR results on days 6 and 11 of the follow-up. Drug Safety 174 175 All adverse events reported by the participants during the study period in the 176 electronic patient diary app or during medical consultations were recorded. To 177 assess the safety of the drug, QT intervals were measured by a certified cardiologist 178 using the Bazett formula by performing a 12-lead electrocardiogram at the inclusion 179 visit, on days 6 and 11 of the follow-up. Sample Size 180 The sample size was calculated using a comparative study formula. An expected 182 difference of 40% in the clinical response between HCQ+AZT treatment and placebo 183 was considered, with a margin of superiority of 10%, an α error of 5%, and a 184 statistical power of 80%. The estimated sample size obtained from the calculation 185 was 84 participants, 28 participants per group, to which 20% was added for possible 186 losses, obtaining a sample size of 105 participants. Due to the decrease in the 187 number of COVID-19 patients, only 92 participants were included. Statistical Analysis 188 189 Therapeutic Efficacy Analysis: 190 The therapeutic efficacy was assessed using an intention-to-treat analysis. The 191 variables considered for the determination of efficacy were as follows: 192 hospitalization, disease progression, pneumonia, and use of supplemental oxygen.

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Clinical Safety Analysis: The safety analysis was carried out considering all the participants regardless of their completion of the study. The frequency and severity of the adverse events presented by the participants during the study were determined, and a comparison was made according to the types of treatment given using the Pearson's X²test or Fischer exact test. Descriptive and Inferential Statistics A descriptive analysis was carried out to determine the general characteristics of the population [16]. To determine if there were differences in the baseline status of the population by the treatment assignment, the ANOVA test was used for systolic and diastolic pressure, PCR (CT), total leukocytes and lymphocytes, the Kruskal-Wallis test was used for age, BMI, temperature, oxygen saturation, NEWS Score, Glucose, urea, lactic dehydrogenase, GGT, transaminases, serum iron, neutrophils and platelets, and the Pearson's X² test or Fisher's exact test was used for sex, comorbidities, smoking and Ivermectin. The incidence of hospitalization, disease progression, pneumonia, use of supplemental oxygen and negative test (PCR) on day 11 was determined according to the treatment assignment as a measure of association. The relative risk (RR) was calculated, with its 95% confidence interval, and the number needed to treat (NNT) and number needed to harm (NNH) were calculated as a measure of potential impact [17]. Alpha was set at 5%, all data were analyzed by using IBM SPSS v.28 (IBM Corp., NY, USA).

Results 217 Study population 218 219 Figure 1 shows the number of participants included in the study and assigned to 220 treatments. A total of 92 participants were randomized between January and June 221 2021 and included in the intention-to-treat analysis. In the per-protocol analysis, 6 222 participants were excluded, four patients for withdrawing informed consent in the 223 HCQ+AZT group and one for medication error, and one participant for withdrawing 224 informed consent in the HCQ group. None of the patients was excluded in the 225 placebo group. 226 The general characteristics of the population are shown in Table 1. The median age 227 was 37 years, 27.2% of the patients had comorbidities, the median BMI was 26.9. 228 The analysis of the time of evolution at the initiation of treatment revealed a median of 5 days, with a median saturation of 94%. The incidence of hospitalization in the 229 230 study population was 2.2%. The analysis of the laboratory studies revealed that 27.2% of the participants had elevated lactic dehydrogenase levels, 45.7% had 231 232 elevated gamma-glutamyl transferase levels, 48.9% had elevated levels of some 233 type of transaminase, 8.7% had neutropenia, and 21.7% had thrombocytopenia at 234 the beginning of the study. 235 The analysis of the symptoms at the beginning of the study showed that 81.5% of 236 the participants had a cough, 77.2% had a headache, 62% had fatigue, 32.6% had 237 a fever, 23.9% had arthralgia, 8.7% had dyspnea, 23.9% had a sore throat, 32.6% 238 had anosmia, and 30.4% had dysgeusia.

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

Table 2 shows the baseline characteristics of the population according to the allocation to the treatment arm. There were no significant differences for any of the variables analyzed. Primary Outcome The analysis of the therapeutic efficacy to reduce the risk of hospitalization revealed that the incidence of the outcome in the HCQ+AZT group was 6.7% (2/30) compared to the HCQ group and the placebo group, in which there were no hospitalizations (Table 3). Secondary Outcomes The incidence of disease progression was 30% (9/30) in the HCQ+AZT group, 41.9% (13/31) in the HCQ group, and 12.9% (4/31) in the placebo group. The RR for the HCQ+AZT group versus placebo was 2.32 (95% CI, 0.80-6.74; p=0.10) and the RR for the HCQ group versus placebo was 3.25 (95% CI, 1.19-8.87; p=0.01). Even though there was a statistically significant risk for developing pneumonia in the HCQ group compared to the placebo group [RR=3.33 (CI 95% 1.10, 10.9; p=0.02)]. the pneumonia incidence was 30% (9/30) in the HCQ+AZT group, 32.2% (10/31) in the HCQ group and 9.6% (3/31) in the placebo group. The fixed combination of HCQ+AZT did not benefit compared to placebo. The frequency of patients who required supplemental oxygen was 20% (6/30) in the HCQ+ AZT group, 6.4% (2/31) in the HCQ group, and 3.2 % (1/31) in the placebo group. There were no significant differences between the groups. (Figure 1) There was no statistical difference between groups for negative test (PCR) on day 11. Table 4 shows the efficacy of a placebo for secondary outcomes. For the group receiving placebo, we found disease progression in 12.9% (4/31) of participants

264

265

266

267

268269

270

271

272

273

274

275

276277

278

279

280

281

282

283

284

285

compared to the group receiving active drugs (HCQ+AZT, HCQ) in 36.1% (22/61). [RR of 0.35 (0.13, 0.94; p=0.02)]. When analyzing pneumonia development, the results showed an incidence of 9.6% (3/31) compared to an incidence of 31% (19/61) in the group with HCQ+AZT, HCQ, [RR of 0.31 (0.09, 0.96, p=0.02)]. We could not observe differences in the use of supplemental oxygen. Adverse Events The most frequent adverse events were gastrointestinal symptoms with a rate of 16.6% (nausea, vomiting, heartburn, abdominal pain and distension), bradycardia with a rate of 6.4%, platelet elevation with a rate of 4.3%, and hypertriglyceridemia with a rate of 3.8%. Adverse events occurred with similar frequency between the different treatment groups. The analysis of whether there were differences in the QTc interval by the treatment group showed no differences in those who received HCQ+AZT or HCQ compared to the placebo group (Table 5). Discussion At the beginning of the pandemic, the fixed combination of HCQ +AZT was proposed as a possible therapeutic option based on its antiviral and anti-inflammatory activity in vitro. However, clinical studies yielded inconsistent results. Therefore, this research project is conducted [18]. The study population consisted of participants with mild COVID-19, who had a low risk of complications. Of whom, only 2% required hospitalization. These data coincide with those reported in a population study from Alberta, Canada [19]. The results of this study suggest that the fixed combination of HCQ+AZT for the treatment of patients with mild COVID-19 does not reduce the risk of hospitalization

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

compared to the use of HCQ alone or placebo. These results coincide with those reported in a Brazilian clinical trial on patients with mild and moderate COVID-19. which showed no significant differences for any of the treatment groups (HCQ+AZT, HCQ, or placebo) in terms of hospitalization or mechanical ventilation [20]. These results also coincide with those reported by other authors who evaluated the separate use of HCQ or AZT and found no benefit to reduce the risk of hospitalization, mechanical ventilation, or mortality [11,21–25]. The analysis of the secondary outcomes revealed that the administration of HCQ increased the risk of progression and pneumonia compared to placebo. However, for the combination of HCQ+AZT, the results showed only a trend in the risk for pneumonia, with no statistical significance, due to lack of statistical power. When we combined both active treatments against placebo for progression and pneumonia, we were able to show these differences. The increase in the risk of damage after the use of the combination of HCQ+AZT, as in this study, was also reported by Kureder et al. who found a higher risk of mortality in patients who received this combination treatment, even in the multivariate model. However, these results were derived from an observational study where it was possible that the patients who received the use of HCQ+AZT had a more severe form of the disease at baseline, while in the present study, the participants included in the three treatment groups had mild symptoms [26]. Our results on the lack of benefit for the different outcomes of the study contrast with the results reported by Gautret et al., who highlighted the efficacy of the combination of HCQ+AZT for viral clearance on day six of treatment, in this study, no significant differences were found in the negativization of the PCR at day 11. It

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

is possible to attribute the differences to the design of the study, nonrandomization, the evaluation of an intermediate regulator as an outcome, and not evaluating other clinically relevant outcomes such as mechanical ventilation or mortality [27]. Although an antiviral effect against SARS-CoV-2 was found for HCQ and AZT in vitro, the use of HCQ in this study conditioned a higher risk of progression and pneumonia. This paradoxical response suggests that the drug could impair the immune response, conditioning a delay in the cellular and adaptive immune response, as shown by Roques et al. analyzing the effect of chloroguine on Chikungunya virus infection, who highlighted the contrast between the in vitro antiviral effect of chloroquine and the exacerbation of the disease in vivo and who reported that they are like the results reported by Maisonnasse, as well as our results [28,29]. Another concern about the use of HCQ+AZT for the treatment of COVID-19 infection is the risk of cardiovascular complications by prolonging the QT interval and causing polymorphic ventricular tachycardia in the form of Torsade de Pointes and death [30]. In this study, no differences in QT segment duration or fatal arrhythmias were documented in the three treatment groups, suggesting that significant cardiac involvement and arrhythmias in patients infected with COVID-19 have a multifactorial etiology and are more common in patients with severe forms of the disease, comorbidities, and advanced age [31, 32]. The absence of cardiovascular complications in our population can be explained by the inclusion of a young population, with a low prevalence of comorbidities and mild disease.

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350351

352

353

354

355

The most frequent adverse events were mild and gastrointestinal symptoms. characterized by nausea, vomiting, pain, and abdominal distension. The sample size calculation was 105 participants. However, the study was stopped after the inclusion of 92 participants due to a decrease in the number of patients in Mexico prior to the third pandemic wave. Participants who received ivermectin as concomitant treatment were included. However, the use or Ivermectin wasn't associated with hospitalization, pneumonia and disease progression. Conclusion The use of HCQ+AZT did not show efficacy in reducing the risk of hospitalization in patients with mild COVID-19 with controlled comorbidities. The use of HCQ and HCQ+AZT was associated with an increased risk of disease progression. The adverse events observed were mild and infrequent, predominantly consisting of gastrointestinal symptoms, without presenting cardiac alterations. Digital monitoring is a very valuable tool for the early detection of infection progression data. It is important to emphasize that empirical treatments were administered during the initial phases of the pandemic. It is important to continue generating evidence on this disease based on randomized control trials. Acknowledgments This study is part of the doctoral studies at the Instituto Politécnico Nacional of the doctoral candidate Ivonne Anali Roy-Garcia. We would like to thank all the patients who participate in this study, nevertheless all the requirements of the protocol. We also like to thank the directors of the Organ of Decentralized Administrative Operation Regional State of Mexico East and the

356 directors of the Family Medicine Unit 52 Cuautitlán Izcalli and the Family Medicine 357 Unit 28 for the facilities to carry out this research. Chief of Medical Benefit 358 Services, Dr. María de los Ángeles Dichi Romero, Coordinator of Planning and 359 Institutional Liaison, Dr. Olga Margarita Bertadillo Mendoza, Director of UMF 52, 360 Dr. Irlanda León Bojorges and to the laboratory staff of the UMF 28 and the 361 epidemiology, Dra. Brenda Jessica Espinosa Armenta. References 362 363 1. Coronaviridae Study Group of the International Committee on Taxonomy of 364 Viruses. The species Severe acute respiratory syndrome-related coronavirus: 365 classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 366 Apr;5(4):536-44. 367 2. Huang M, Yang Y, Shang F, Zheng Y, Zhao W, Luo L, Han X, Lin A, Zhao H, Gu 368 Q, Shi Y, Li J, Xu X, Liu K, Deng Y, Cao Q WW. Clinical Characteristics and 369 Predictors of Disease Progression in Severe Patients with COVID-19 Infection in 370 Jiangsu Province, China: A Descriptive Study. Am J Med Sci. 2020;360(2):120–68. 371 3. Álvarez-Maldonado P, Hernández-Ríos G, Ambríz-Mondragón JC, Gordillo-372 Mena JA, Morales-Serrano DF, Reding-Bernal A, et al. Characteristics and 373 mortality of Mexican patients with COVID-19 and mechanical ventilation. Gac Med 374 Mex. 2021;157(1):97–101. 375 4. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of

hydroxychloroguine in treatment of patients with moderate COVID-19. Zhejiang Da

Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215–9.

376

377

- 5. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M,
- Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira
- VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V,
- Jacquier A, Deharo JC, RD. Clinical and microbiological effect of a combination of
- hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-
- day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663.
- 6. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and
- chloroguine effectively inhibit the recently emerged novel coronavirus (2019-nCoV)
- 386 in vitro. Cell Res. 2020 Mar;30(3):269–71.
- 7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine
- on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003
- 389 Nov;3(11):722–7.
- 8. Andreani J, le Bideau M, Duflot I, Jardot PRolland C, Boxberger M, Wurtz N, et
- al. In vitro testing of combined hydroxychloroguine and azithromycin on SARS-
- 392 CoV-2 shows synergistic effect. Microb Pathog. 2020 Aug;145(104228).
- 9. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio
- Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of
- 395 COVID-19: a review. Expert Rev Anti Infect Ther. 2021 Feb 19;19(2):147–63.
- 10. Kelly M, O'Connor R, Townsend L, Coghlan M, Relihan E, Moriarty M, et al.
- 397 Clinical outcomes and adverse events in patients hospitalised with COVID-19,
- treated with off-label hydroxychloroguine and azithromycin. Br J Clin Pharmacol.
- 399 2021 Mar;87(3):1150-4.

- 400 11. Albani F, Fusina F, Giovannini A, Ferretti P, Granato A, Prezioso C, et al.
- Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-
- 402 19. J Clin Med. 2020 Aug 30;9(9):2800.
- 403 12. Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, Leone M,
- La Scola B, Devaux C, Gaubert JY, Mege JL, Vitte J, Melenotte C, Rolain JM,
- Parola P, Lagier JC, Brouqui P RD. Natural history of COVID-19 and therapeutic
- 406 options. Expert Rev Clin Immunol. 2020;16(12):1159–84.
- 407 13. Kim EJ, Coppa K, Hirsch JS, Abrahams S, Johnson J, Lesser M, et al.
- Examination of patient characteristics and hydroxychloroguine use based on the
- 409 US Food and Drug Administration's recommendation: a cross-sectional analysis in
- 410 New York. . BMJ Open. 2021;11(2):e042965.
- 411 14. Secretaria de Salud de México. Lineamiento estandarizado para la vigilancia
- 412 epidemiológica y por laboratorio de COVID-19" aprobado por el Comité Nacional
- 413 para la Vigilancia Epidemiológica (CONAVE). 2020.
- 414 15. Morgenstern-Kaplan D, Buitano-Tang B, Martínez-Gil M, Zaldívar-Pérez Pavón
- 415 A, Talavera JO. U-shaped-aggressiveness of SARS-CoV-2: Period between initial
- 416 symptoms and clinical progression to COVID-19 suspicion. A population-based
- 417 cohort study. PLoS One. 2020 Dec 3;15(12):e0243268.
- 418 16. Talavera JO, Rivas-Ruiz R. Clinical research IV. Relevancy of the statistical
- 419 test chosen. Rev Med Inst Mex Seguro Soc. 2011;49(4):401–5.
- 420 17. Rivas-Ruiz R, Roy-García I, Pérez-Rodríguez M, Berea R, Moreno-Palacios J,
- 421 Moreno-Noguez M, et al. The relevance and irrelevance of charts in clinical
- 422 research. Rev Alerg Mex. 2020 Dec;67(4):381–96.

- 18. Andreani J, le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In
- vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2
- shows synergistic effect. Microb Pathog. 2020 Aug;145:104228.
- 426 19. Schwartz I, Boesen ME, Cerchiaro G, Doram C, Edwards BD, Ganesh A, et al.
- 427 Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of
- 428 COVID-19: a randomized controlled trial. 2021 Jun 18;9(2):E693-E702. . CMAJ
- 429 Open. 2021 Jun 18;9(2):693–702.
- 20. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et
- al. Hydroxychloroguine with or without Azithromycin in Mild-to-Moderate Covid-19.
- 432 N Engl J Med. 2020 Nov 19;383(21):2041–52.
- 433 21. Skipper CP PKENBAAMLSW da. Hydroxychloroquine in Nonhospitalized
- 434 Adults With Early COVID-19: A Randomized Trial. Ann Intern Med. 2020
- 435 Oct:173(8):623–31.
- 436 22. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
- with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
- 438 Lancet. 2021 Feb 13;397(10274):605–12.
- 439 23. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of
- suspected COVID-19 in people at increased risk of an adverse clinical course in
- the UK (PRINCIPLE): a randomized, controlled, open-label, adaptive platform trial.
- 442 Lancet. 2021 Mar 20;397(10279):1063–74.
- 24. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational
- Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med
- 445 2020 Jun 18;382(25):2411-2418. 2020 Jun 18;382(25):2411–8.

- 25. Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park
- 447 JJH, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and
- 448 Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The
- 449 TOGETHER Randomized Clinical Trial. . JAMA Netw Open. 2021 Apr
- 450 1;4(4):e216468.
- 26. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al.
- 452 Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
- 453 Lancet. 2020 Jun 20;395(10241):1907–18.
- 454 27. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
- 455 Hydroxychloroguine and azithromycin as a treatment of COVID-19: results of an
- open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020
- 457 Jul;56(1):105949.
- 458 27. Rogues P, Thiberville SD, Dupuis-Maguiraga L, Lum FM, Labadie K, Martinon
- 459 F, et al. Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya
- 460 Virus Infection. Viruses. 2018 May 17;10(5):268.
- 28. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al.
- 462 Hydroxychloroguine use against SARS-CoV-2 infection in non-human primates.
- 463 Nature 2020. 2020 Sep;585(7826):584–7.
- 464 29. Manolis AS, Manolis AA, Manolis TA, Apostolopoulos EJ, Papatheou D, Melita
- 465 H. COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med 2020
- 466 Nov;30(8):451-460 . 2020;30(8):451-60.
- 467 30. Ramadan MS, Bertolino L, Zampino R, Durante-Mangoni E, Monaldi Hospital
- 468 Cardiovascular Infection Study Group. Cardiac seguelae after coronavirus disease
- 2019 recovery: a systematic review. Clin Microbiol Infect. 2021 Sep;27(9):1250–61.

31. Garcia-Zamora S, Lee S, Haseeb S, Bazoukis G, Tse G, Alvarez-Garcia J, et al. Arrhythmias and electrocardiographic findings in Coronavirus disease 2019: A systematic review and meta-analysis. Pacing Clin Electrophysiol. 2021

Jun;44(6):1062–74.

Table 1. Baseline characteristics of participants

l vermectin (n,%) b BMI (Kg/m²) b 26.9 (24.4-30.1) Weight status (n,%) c Normal weight Overweight Obesity Temperature (°C) b Systolic pressure (mmHg) a Diastolic pressure (mmHg) a 11 (12) 26.9 (24.4-30.1)	Variables	n=92
Comorbidities (n,%) ° 25 (27.2) Smoking (n,%) ° 32 (34.8) bib hypothology (n, 10) ° 32 (34.8) bib hypothology (n, 10) ° 32 (34.8) bib hypothology (n, 10) ° 32 (34.8) local hypothology (n, 10) ° 11 (12) BMI (Kg/m²) b 26.9 (24.4-30.1) Weight status (n,%) ° 28 (30.4) Normal weight 28 (30.4) Overweight 41 (44.6) Obesity 23 (25) Temperature (°C) b 36.6 (36.4-36.8) Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a 78.6 ± 8.4 Corrected QT segment (ms) b 415.5 (394.2-432.7) Oxygen saturation (%) b 94 (93-96) NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) ° 42 (45.7) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Age (years) b	37 (27.5-50.5)
Smoking (n,%) ° do: https://doi.org/10.1101/2022.04.06.22273531: this version posted April 16, 2022. The copyright holder for this propertic certified by peer review) is the authorization who has granted meditow a license to deplay the preprint in perpetuit. I (12) BMI (Kg/m²) b 26.9 (24.4-30.1) Weight status (n,%) ° Normal weight 28 (30.4) Overweight Overweight Obesity 23 (25) Temperature (°C) b 36.6 (36.4-36.8) Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a Corrected QT segment (ms) b NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b Elevated DHL (n,%) ° Elevated DHL (n,%) ° Elevated de Glutamic Pyruvic Transaminase (n,%) c	Male sex (n,%) ^c	45 (48.9)
the https://doi.org/10.1012/20.04.08.2927/33.1 this version posted April 16, 2022. The copyright holder for this preprint cortillar by performance in the properties. I (12) BMI (Kg/m²) b 26.9 (24.4-30.1) Weight status (n,%) c Normal weight 28 (30.4) Overweight 41(44.6) Obesity 23 (25) Temperature (°C) b 36.6 (36.4-36.8) Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a 78.6 ± 8.4 Corrected QT segment (ms) b 415.5 (394.2-432.7) Oxygen saturation (%) b 94 (93-96) NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b 5 (3, 6) Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Comorbidities (n,%) ^c	25 (27.2)
11 (12)	doi: https://doi.org/10.1101/2022.04.06.22273531; this version posted April 16, 2022. The copyright holder for this pre	eprint
Weight status (n,%) ° Normal weight 28 (30.4) Overweight 41(44.6) Obesity 23 (25) Temperature (°C) b 36.6 (36.4-36.8) Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a 78.6 ± 8.4 Corrected QT segment (ms) b 415.5 (394.2-432.7) Oxygen saturation (%) b 94 (93-96) NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) ° 42 (45.7) Elevated DHL (n,%) ° 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	certified by near review) is the author/funder, who has granted medRyly a license to display the preprint in perpetu	ity.
Normal weight 28 (30.4) Overweight 41(44.6) Obesity 23 (25) Temperature (°C) b 36.6 (36.4-36.8) Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a 78.6 ± 8.4 Corrected QT segment (ms) b 415.5 (394.2-432.7) Oxygen saturation (%) b 94 (93-96) NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) c 42 (45.7) Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	BMI (Kg/m²) b	26.9 (24.4-30.1)
Overweight $41(44.6)$ Obesity $23 (25)$ Temperature (°C) b $36.6 (36.4-36.8)$ Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a 78.6 ± 8.4 Corrected QT segment (ms) b $415.5 (394.2-432.7)$ Oxygen saturation (%) b $94 (93-96)$ NEWS (score) a $1 (0, 2)$ Time of evolution until treatment start (days) b $5 (3, 6)$ Elevated Gammaglutamyl transferase (n,%) c $42 (45.7)$ Elevated DHL (n,%) c $25 (27.2)$ Elevated de Glutamic Pyruvic Transaminase (n,%) $24 (26.1)$	Weight status (n,%) ^c	
Obesity 23 (25) Temperature (°C) b 36.6 (36.4-36.8) Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a 78.6 ± 8.4 Corrected QT segment (ms) b 415.5 (394.2-432.7) Oxygen saturation (%) b 94 (93-96) NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) c 42 (45.7) Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Normal weight	28 (30.4)
Temperature (°C) b Systolic pressure (mmHg) a 117.7 ± 13.7 Diastolic pressure (mmHg) a 78.6 ± 8.4 Corrected QT segment (ms) b Oxygen saturation (%) b NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b Elevated Gammaglutamyl transferase (n,%) c Elevated DHL (n,%) c Elevated de Glutamic Pyruvic Transaminase (n,%) c	Overweight	41(44.6)
Systolic pressure (mmHg) a 117.7 \pm 13.7 Diastolic pressure (mmHg) a 78.6 \pm 8.4 Corrected QT segment (ms) b 415.5 (394.2-432.7) Oxygen saturation (%) b 94 (93-96) NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) c 42 (45.7) Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Obesity	23 (25)
Diastolic pressure (mmHg) ^a 78.6 ± 8.4 Corrected QT segment (ms) ^b $415.5 (394.2-432.7)$ Oxygen saturation (%) ^b $94 (93-96)$ NEWS (score) ^a $1 (0, 2)$ Time of evolution until treatment start (days) ^b $5 (3, 6)$ Elevated Gammaglutamyl transferase (n,%) ^c $42 (45.7)$ Elevated DHL (n,%) ^c $25 (27.2)$ Elevated de Glutamic Pyruvic Transaminase (n,%) $24 (26.1)$	Temperature (°C) b	36.6 (36.4-36.8)
Corrected QT segment (ms) b Oxygen saturation (%) b NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b Elevated Gammaglutamyl transferase (n,%) c Elevated DHL (n,%) c Elevated de Glutamic Pyruvic Transaminase (n,%) c	Systolic pressure (mmHg) ^a	117.7 <u>+</u> 13.7
Oxygen saturation (%) b NEWS (score) a 1 (0, 2) Time of evolution until treatment start (days) b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) c 42 (45.7) Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Diastolic pressure (mmHg) a	78.6 <u>+</u> 8.4
NEWS (score) ^a 1 (0, 2) Time of evolution until treatment start (days) ^b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) ^c 42 (45.7) Elevated DHL (n,%) ^c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Corrected QT segment (ms) b	415.5 (394.2-432.7)
Time of evolution until treatment start (days) b 5 (3, 6) Elevated Gammaglutamyl transferase (n,%) c 42 (45.7) Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Oxygen saturation (%) ^b	94 (93-96)
Elevated Gammaglutamyl transferase (n,%) c 42 (45.7) Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1) c	NEWS (score) a	1 (0, 2)
Elevated DHL (n,%) c 25 (27.2) Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Time of evolution until treatment start (days) b	5 (3, 6)
Elevated de Glutamic Pyruvic Transaminase (n,%) 24 (26.1)	Elevated Gammaglutamyl transferase (n,%) c	42 (45.7)
С	Elevated DHL (n,%) ^c	25 (27.2)
	Elevated de Glutamic Pyruvic Transaminase (n,%)	24 (26.1)
Elevated Glutamic Oxaloacetic Transaminase (n,%) 46 (50)	c	
	Elevated Glutamic Oxaloacetic Transaminase (n,%)	46 (50)

С	
Anemia (n,%) ^c	45 (48.9)
Leukopenia (n,%) ^c	10 (10.9)
Leukocytosis (n,%) ^c	1 (1.1)
Neutropenia (n,%) ^c	8 (8.7)
Neutrophilia (n,%) ^c	3 (3.3)
Lymphopenia (n,%) ^c	27 (29.3)
t doi: nime/(spines/10.4101/2022.04.06-22278531.dhis version posted April 16, 2022. The copyright holder for this preprint of certified by peer veryes) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.	20 (21.7)

^a Data is presented as Mean and Standard Deviation, ^b data is presented as median and interquartile range 25-75 (IQR), ^c data is presented as frequencies and percentages.

Table 2. General characteristics according to treatment arm

Variables	Total	HCQ	HCQ+AZT	Placebo	р
	n= 92	n=31	n=30	n=31	
Age (years) b	37 (27.5-50.5)	38 (24-49.5)	41 (33.7-49.5)	32 (24-51)	0.34
Male sex (n,%) °	45 (48.9)	13 (41.9)	12 (40.0)	20 (64.5)	0.07
Comorbidities (n,%) °	25 (27.2)	9 (29.0)	7 (23.3)	9 (29.0)	1.0
Smoking (n,%) °	32 (34.8)	10 (32.3)	9 (30.0)	13 (41.9)	0.42
Time of evolution until treatment start	5 (3, 6)	5 (4, 6)	5 (3, 6)	5 (3, 7)	0.78
(days) ^b					
BMI (Kg/m²) b	26.9 (24.4- 30.1)	26.9 (24.6-28.6)	27.3 (25.2-30.4)	25.6 (24.1-31.7)	0.53
Temperature (°C) b	36.6 (36.4-36.8)	36.7 (36.4-36.8)	36.6 (36.4-36.8)	36.6 (36.5- 36.8)	0.97
Systolic pressure (mmHg) ^a	117.7 <u>+</u> 13.7	117.2 <u>+</u> 13.9	117.0 <u>+</u> 12.5	118.3 <u>+</u> 14.7	0.93
Diastolic pressure (mmHg) ^a	78.6 <u>+</u> 8.4	78.3 <u>+</u> 8.1	78.5 <u>+</u> 8.8	78.9 <u>+</u> 8.8	0.97
Oxygen saturation (%) ^b	94 (93-96)	95 (93.7-96)	94 (92-95)	94 (93-96)	0.53
NEWS (score) b	1 (0,2)	0.5 (0, 2)	1 (0, 2)	2 (0, 2)	0.43
PCR (CT) *	26.6 <u>+</u> 4.7	26.2 <u>+</u> 4.8	26.4 <u>+</u> 4.9	27.1 <u>+</u> 4.5	0.72

Glucose (mg/dL) b	88.7 (79.3-96.3)	92.4 (75.5-101.6)	88.2 (78.8-99.5)	84.6 (79.6-92.5)	0.2
GidCose (ilig/dL)	00.7 (79.3-90.3)	32.4 (73.3-101.0)	00.2 (70.0-99.5)	04.0 (75.0-52.5)	0.2
Urea (mg/dL) a	25.5 (21.1-33.1)	26.8 (21.0-33.6)	25.1 (19.5-33.3)	24.9 (22.1-32.8)	0.8
Lactic dehydrogenase (U/L) b	196.6 (164.6-221.1)	198.3 (158.4-231.4)	194.5 (167.7-	182.9 (166.5-220.6)	0.9
			217.5)		
Gamma Glutamil Transferasa (U/L) b	32.9 (21.1-66.1)	31.8 (21.2-66.9)	35.8 (19.2- 73.3)	32.8 (21.9-65.7)	0.9
Glutamic Pyruvic Transaminase (U/L) b	33.6 (19.9- 55.3)	36.7 (21.6- 54.1)	33.4 (23.3- 58.7)	24.2 (15.4-54.3)	0.4
Glutamic Oxaloacetic Transaminase	31.5 (25.3- 44.5)	32.1 (27.7- 46.8)	32.0 (24.7- 42.1)	29.6 (23.7- 40.8)	0.5
(U/L) ^b					
Serum iron (ug/dL) ^a	50.8 (35.4-69.4)	48.5 (32.7- 69.8)	55.1 (37.6- 73.2)	47.2 (35.3-65.3)	0.5
Total leukocytes (K/μL) ^a	4.99 <u>+</u> 1.49	5.1 <u>+</u> 1.5	5.1 <u>+</u> 1.6	4.8 <u>+</u> 1.2	0.7
Neutrophils (K/μL) b	2.7 (2.3-3.8)	2.7 (2.3-4.1)	2.8 (2.1- 3.9)	2.7 (1.9-3.7)	0.7
Lymphocytes (K/μL) ^a	1.2 <u>+</u> 0.4	1.2 <u>+</u> 0.4	1.2 <u>+</u> 0.4	1.2 <u>+</u> 0.4	0.9
Platelets (K/μL) b	212 (172-256.5)	212 (175-257)	202 (157.7- 266)	218.5 (181-257.5)	0.7

^a Data is presented as Mean, Standard Deviation and statistical was done was ANOVA, ^b data is presented as median and interquartile range 25-75 (IQR), statistical test was Kruskal Wallis, ^c data is presented as frequencies and percentages, statistical test was X²

Table 3. Efficacy of treatment for primary and secondary outcomes

Outcomes	HCQ+AZT	HCQ	Placebo	HCQ+AZT vs	NNH	р	HCQ vs	NNH	p
				Placebo RR (CI			Placebo		
	n=30	n=31	n=31	95%			RR (IC 95%)		
Primary									
Hospitalization	2 (6.7%)	0 (0%)	0 (0%)	NC			NC		
Secondary									
outcomes									
Progression	9 (30%)	13	4 (12.9%)	2.32 (0.80 6.74)	-	0.10	3.25 (1.19, 8.87)	-	0.01
		(41.9%)							
Pneumonia	9 (30%)	10	3 (9.6%)	3.1 (0.92, 10.3)	4.7	0.06	3.33 (1.01, 10.9)	4.4	0.02
		(32.2%)							
Use of	6 (20%)	2 (6.4%)	1 (3.2%)	6.2 (0.79, 48.4)		0.10	2.0 (0.19, 20.9)	-	0.61
supplementary									
oxygen									

Negativ	e test on day	21 (87.5%)	27 (90%)	30 (96.8%)	0.90 (0.76-1.06)	-	0.30	0.93 (0.81-1.06)	-	0.354
11 a										

a Data were missing for 7 patients in the group with HCQ+AZT

Figure 1. Efficacy of HCQ+AZT vs placebo for secondary outcomes




Figure 2. Efficacy of HCQ vs placebo for secondary outcomes




Table 4. Efficacy of placebo vs active treatment for primary and secondary outcomes

Outcomes	Placebo	Otros tratamientos	RR	р	NNT	RAR
	n=31	n=61				
Secundary						
Progression	4 (12.9%)	22 (36.1%)	0.35 (0.13, 0.94)	0.02	4.3	23.2
Pneumonia	3 (9.6%)	19 (31%)	0.31 (0.09, 0.96)	0.02	4.6	21.4
Use of supplementary oxygen	1 (3.2%)	8 (13.1%)	0.24 (0.03, 1.87)	0.13	-	-

Table 5. Adverse events according to treatment group

Adverse event	Total	HCQ+AZT	HCQ	Placebo	р
	559	177	213	169	
Duration of the QTc	416 (390- 434)	413 (387-439)	421 (396-430)	413 (384-	0.903
segment (ms) at the end				435)	
of the follow-up a					
Gastrointestinal, n (%)	93 (16.6)	33 (18.6)	36 (16.9)	24 (14.2)	0.269
Urticaria, n (%)	5 (0.9)	0 (0)	4 (1.9)	1 (0.6)	0.541
Dizziness, n (%)	14 (2.5)	3 (1.7)	5 (2.3)	6 (3.6)	0.271
Hypoglicemia, n (%)	12 (2.1)	3 (1.7)	4 (1.9)	5 (3.0)	0.421
Thrombocytosis, n (%)	24 (4.3)	6 (3.4)	9 (4.2)	9 (5.3)	0.376
Hypertriglyceridemia, n	21 (3.8)	5 (2.8)	8 (3.8)	8 (4.7)	0.508
(%)					
Bradycardia, n (%)	36 (6.4)	13 (7.3)	11 (5.2)	12 (7.1)	0.916
Others, n (%)	349 (62.4)	111 (62.4)	134 (62.9)	104 (61.5)	0.573

Median, interquartile range, Kruskal Wallis test